ArticleFrontiers in aging neuroscience2020
Metabolic Profiling of Cognitive Aging in Midlife.
Article in Frontiers in aging neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Exploratory bidirectional Mendelian randomisation analysis of cerebrospinal fluid metabolites associated with cerebral palsy and epilepsy.BMJ paediatrics open · 2026Article
- A metabolomic clock of population ageing: cross-cohort validation and associations with frailty and cognitive function.GeroScience · 2026Article
- NRF2 as a guardian of health: from an ancient survival pathway to a modern therapeutic target.Redox biology · 2026Review
- Serum metabolic signatures of cognitive resilience in a longitudinal aging cohort.bioRxiv : the preprint server for biology · 2026Article
- Sex-Specific Biological Aging-Related Lipidomic Profiles Mediate the Impact of Urinary Polycyclic Aromatic Hydrocarbon Exposures on Cognitive Function in Healthy Older Adults.Environment & health (Washington, D.C.) · 2026Article
- Untargeted Lipidomic Reveals Potential Biomarkers in Plasma Samples for the Discrimination of Patients Affected by Parkinson's Disease.Molecules (Basel, Switzerland) · 2025Article
- Association between metabolomics-based biomarker scores and 10-year cognitive decline in men and women. The Doetinchem Cohort Study.Age and ageing · 2024Article
- A Subtype Perspective on Cognitive Trajectories in Healthy Aging.Brain sciences · 2024Article
- Impact of Bariatric Surgery on Circulating Metabolites and Cognitive Performance.Obesity surgery · 2024Article
- Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer's disease.Alzheimer's research & therapy · 2023Article
- The gut-derived metabolites as mediators of the effect of healthy nutrition on the brain.Frontiers in nutrition · 2023Review
- The role of dietary patterns and erythrocyte membrane fatty acid patterns on mild cognitive impairment.Frontiers in nutrition · 2022Article
- Cognitive flexibility and brain network energy in healthy aging: An allostatic perspective from the SENECA model.Imaging neuroscience (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Alzheimer's dementia (AD) begins many years before its clinical symptoms. Metabolic dysfunction represents a core feature of AD and cognitive impairment, but few metabolomic studies have focused on cognitive aging in midlife. Using an untargeted metabolomics approach, we identified metabolic predictors of cognitive aging in midlife using fasting plasma sample from 30 middle-aged (mean age 57.2), male-male twin pairs enrolled in the Vietnam Era Twin Study of Aging (VETSA). For all twin pairs, one twin developed incident MCI, whereas his co-twin brother remained to be cognitively normal during an average 5.5-year follow-up. Linear mixed model was used to identify metabolites predictive of MCI conversion or cognitive change over time, adjusting for traditional risk factors. Results from twins were replicated in an independent cohort of middle-aged adults (mean age 59.1) in the Wisconsin Registry for Alzheimer's Prevention (WRAP). Results in twins showed that higher baseline levels of four plasma metabolites, including sphingomyelin (d18:1/20:1 and d18:2/20:0), sphingomyelin (d18:1/22:1, d18:2/22:0, and d16:1/24:1), DAG (18:2/20:4), and hydroxy-CMPF, were significantly associated with a slower decrease in one or more domains of cognitive function. The association of sphingomyelin (d18:1/20:1 and d18:2/20:0) was replicated in WRAP. Our results support that metabolic perturbation occurs many years before cognitive impairment and plasma metabolites may serve as early biomarkers for prediction or monitoring of cognitive aging and AD in midlife.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.